A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Inclusion Criteria: * Be a current, recreational, not physically dependent, drug user * Participant must be medically stable * All female participants must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine pregnancy test on Day -1 of the qualification phase and on Day -1 of each treatment period of the treatment Phase * Blood pressure (after the participant is in a sitting position for 5 minutes) between 90 millimeters of mercury (mmHg) and 160 mmHg systolic, inclusive, and no higher than 100 mmHg diastolic at screening and Day -1 prior to qualification phase randomization * A 12-lead ECG consistent with normal cardiac conduction and function, including: sinus rhythm, pulse rate between 40 and 100 beats per minute (bpm), QTc interval less than or equal to (\<=) 450 milliseconds (ms) for males, \<=470 for females, QRS interval of less than (\<) 120 ms, PR interval \<210 ms, Morphology consistent with healthy cardiac conduction and function Exclusion Criteria: * Known allergies to seltorexant, zolpidem, and suvorexant * Previous history of recurrent fainting, collapses, syncope, orthostatic hypotension, or vasovagal reactions * Prescription medications except for stable medical problems such as hypertension, elevated cholesterol, and non-insulin-dependent diabetes mellitus with stable medications for at least 1 month prior to screening * Participants who have ever been in treatment for substance use disorders …